E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Duchenne Muscular Dystrophy |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10013801 |
E.1.2 | Term | Duchenne muscular dystrophy |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluate patient satisfaction in response to testosterone replacement therapy in DMD patients with pubertal delay. |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the effect of a standard incremental regimen of intramuscular testosterone therapy on pubertal staging, testicular volume and sex hormone levels • Evaluate the effect of testosterone replacement therapy on growth • Evaluate the effect of testosterone replacement therapy on muscle strength, mass and function in adolescents with DMD • Evaluate the effect of testosterone replacement therapy on muscle pathology as assessed by muscle MRI in DMD patients • Evaluate the effect of testosterone replacement therapy on bone mineral density and body composition in adolescents with DMD • Characterise the side-effect profile when using a standard incremental regimen of intramuscular testosterone therapy
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• A molecular diagnosis of Duchenne Muscular Dystrophy. • Pre-pubertal males aged between 12 and 17 years of age at time of first dosing (Tanner stage 1, testicular volume <4 mls, initial testosterone level of <2.0 nmol/l) • Patients should receive the standard of care for DMD as recommended by the NorthStar UK and TREAT-NMD guidelines • Patients should be capable of sitting upright in a wheelchair for at least an hour • Patients should be stable from a respiratory point of view. Artificial ventilation with either Bipap or tracheostomy is not a contraindication to the study. • Informed consent signed by the patient (or parent/guardian if under 16 years of age and assent)
|
|
E.4 | Principal exclusion criteria |
• Participants with severe learning difficulties that would preclude them from cooperating with examination. • Anticipated surgery during the study period. • Symptomatic cardiac failure. • Participants/families who may have emotional or psychological problems if recruited to a study • Hypersensitivity to the active substance or to any of the excipients, including arachis oil or derivatives. Sustanon is therefore contraindicated in patients allergic to peanuts or soya. • Any contra-indication to receiving an intramuscular injection • Any additional chronic disease that affects androgen production • Anti-coagulant therapy • None of the current treatments for DMD are exclusion criteria • If participation in the study is not recommended in the opinion of the investigators
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The quantitative primary outcome measure will be a patient reported questionnaire validated to assess subject/parent global satisfaction with treatment, known as the Treatment Satisfaction Questionnaire for Medication (TSQM), version 1.4 The TSQM is a self-administered questionnaire that will be used at baseline, after 1 year of follow-up and at the end of the study. It is a 14-item instrument, yielding four subscale scores: global satisfaction, effectiveness, adverse events and convenience and has been validated for adults with chronic disease. The total score from this will be the primary outcome measure to assess tolerability of testosterone given by intramuscular injection for the induction of pubertal delay. Self-report questionnaires are vital as there is a documented poor correlation between the perceived health related quality of life of adolescents with DMD and the views of their parents. Data has shown that parents grossly underestimate perception of son’s happiness and of perceived support from social networks. The participants will complete questionnaires, with help from their parents if required. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The TSQM will be carried out very 6 months. |
|
E.5.2 | Secondary end point(s) |
1. Subject’s reported effectiveness of testosterone therapy as assessed by semi-structured interviews pre and post treatment 2. Motor function and muscle strength as measured by standardised physiotherapy assessments (Northstar Ambulatory Assessment, Performance of the Upper Limb, timed tests, knee flexion and extension, elbow flexion and extension, shoulder abduction, grip strength and assessment of workable reach space using Kinect) 3. Bone mineral adjusted density of the lumbar spine and total body (minus head) using DXA 4. Assessment of lean versus total body mass assessed by DXA 5. Bone turnover markers (bone-specific alkaline phosphatase, beta crosslaps, osteocalcin, P1NP, RANKL, OPG, sclerostin) 6. Muscle volume and fat fraction as assessed by muscle MRI of upper and lower limbs 7. Pubertal staging assessed using Tanner staging and testicular volume 8. Bone age as assessed by wrist and hand X-Ray 9. Hormonal assessment of pubertal staging (testosterone, LH, FSH and Inhibin B) 10. Forced vital capacity, forced expiratory volume and peak cough flow, measured by spirometry 11.Cardiac function, assessed by ECG and echo
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Bone age and interviews will be carried out at beginning and end of study. Functional tests, hormonal assessment, bone turnover markers, respiratory function and pubertal staging will be performed every 6 months. DXA, cardiac function and MRI will be carried out annually |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 2 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 2 |